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Abstract
Macrophage infiltration is a negative prognostic factor for most cancers but gastrointestinal tumors seem to be an
exception. The effect of macrophages on cancer progression depends on their phenotype, which may vary between M1
(pro-inflammatory, defensive) to M2 (tolerogenic, pro-tumoral). Gastrointestinal cancers often become an ectopic source of
gastrins and macrophages present receptors for these peptides. The aim of the present study is to analyze whether gastrins
can affect the pattern of macrophage infiltration in colorectal tumors. We have evaluated the relationship between gastrin
expression and the pattern of macrophage infiltration in samples from colorectal cancer and the influence of these peptides
on the phenotype of macrophages differentiated from human peripheral monocytes in vitro. The total number of
macrophages (CD68+ cells) was similar in tumoral and normal surrounding tissue, but the number of M2 macrophages
(CD206+ cells) was significantly higher in the tumor. However, the number of these tumor-associated M2 macrophages
correlated negatively with the immunoreactivity for gastrin peptides in tumor epithelial cells. Macrophages differentiated
from human peripheral monocytes in the presence of progastrin showed lower levels of M2-markers (CD206, IL10) with
normal amounts of M1-markers (CD86, IL12). Progastrin induced similar effects in mature macrophages treated with IL4 to
obtain a M2-phenotype or with LPS plus IFNc to generate M1-macrophages. Macrophages differentiated in the presence of
progastrin presented a reduced expression of Wnt ligands and decreased the number and increased cell death of co-
cultured colorectal cancer epithelial cells. Our results suggest that progastrin inhibits the acquisition of a M2-phenotype in
human macrophages. This effect exerted on tumor associated macrophages may modulate cancer progression and should
be taken into account when analyzing the therapeutic value of gastrin immunoneutralization.
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Introduction
Macrophages are a significant component of tumors and display
a variety of functions depending on the local environment. They
can be pro-inflammatory and help to generate adaptive immune
responses (classically activated macrophages, M1) or tolerogenic/
anti-inflammatory (alternatively activated macrophages, M2)
[1,2]. Tumor associated-macrophages (TAMs) often resemble
M2-macrophages and, therefore, instead of fighting against
cancerous cells, these leukocytes promote tumor growth by
dampening the immune response and through the secretion of
growth and angiogenic factors as well as the enzymes necessary for
cell invasion. As a consequence, the presence of TAMs has been
correlated with a decreased survival in patients with e.g.
melanoma, breast, kidney or bladder cancer. The situation seems
to be different in some cancerous processes affecting the
gastrointestinal tract. In patients with colorectal or gastric cancers
a higher macrophage infiltration correlates with a better prognosis
[3]. The reasons for this differential role of macrophages in these
particular diseases is far from clear, but from the current
knowledge one can infer that the colorectal/gastric tumor
microenvironment marks a different equilibrium in the function
of infiltrated M1 and M2 macrophages, with M2 macrophages
exerting a defective opposition to the accompanying M1-
phagocytes [4,5]. However, the mechanisms responsible for this
effect are unknown.
Most adenomatous polyps, colorectal and gastric tumors express
ectopically the gastrin gene. However, these cancer cells are not of
an endocrine nature and mainly synthesize the hormone precursor
progastrin [6–8], which has proliferative action on cancer cells [9].
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Although progastrin may bind with low affinity to gastrin CCK-2
receptors and this interaction may contribute to some extent to its
biological activity [10], progastrin’s growth-promoting effect
appears to be mainly mediated by a non-conventional receptor
recently identified as annexin II [9]. We have observed that gastrin
exerts a pro-inflammatory activity through CCK-2 receptors [11–
13], which are expressed in macrophages and endothelial cells,
while annexin II is highly expressed on the surface of
macrophages, where it serves as a pathogen recognition element
and mediates macrophage activation [14].
Our hypothesis was that gastrin peptides locally produced in
colonic tumors can influence the function of infiltrated macro-
phages and, in this way, modulate the immune response to disease.
We observed that the expression of gastric peptides in colorectal
tumor cells correlates with a reduced infiltration of M2-macro-
phages and showed that progastrin modulates the maturation
process of human macrophages in vitro, and represses the
acquisition of a M2-phenotype. Progastrin also reduced the
secretion of Wnt ligands by M2-macrophages and increased their
ability to induce apoptosis of colon cancer epithelial cells.
Methods
Patients
Twenty-one curatively resected colorectal carcinoma patients
(Table 1) were selected randomly from patients operated at the
Hospital de Manises. None of them had any preoperative radio/
chemotherapy. Immediately after resection, a piece containing
tumor and surrounding normal tissue was fixed in buffered
formalin and embedded in paraffin. Experienced pathologists
documented the histopathological characteristics of the tumors,
including tumor stage, differentiation grade, size, lymph/angioin-
vasion, perineural invasion and lymph node involvement. Tumor
Table 1. Characteristics of patients and tumors.
N (%)
Sex Female 7 (33)
Male 14 (67)
Age 50–60 years 2 (10)
60–70 years 9 (43)
70–80 years 7 (33)
.80 years 3 (14)
Site of primary tumor Colon 15 (71)
Rectum 6 (29)
Tumor differentiation Grade 1 3 (14)
Grade 2 17 (81)
Grade 3 1 (5)
TNM stage T2N0M0 3 (14)
T3N0M0 10 (48)
T3N1M0 1 (5)
T3N1M1 1 (5)
T3N2M0 2 (10)
T3N2M1 1 (5)
T4N0M0 1 (5)
T4N1M0 1 (5)
T4N2M0 1 (5)
doi:10.1371/journal.pone.0098458.t001
Table 2. Antibodies used in immunohistochemistry (IHC) and static cytometry studies.
Antigen Technique Primary antibody Antigen retrieval treatment*
CD68 IHC Monoclonal Mouse Anti-Human CD68 Clone PG-M1 (Dako) a-Chymotrypsin (Sigma), 20 min, 37uC
CD86 IHC B7-2/CD86 (Epitomics) Target Retrieval Solution pH 6 (Dako), 20 min, 95uC
Static cytometry FITC Mouse Anti-Human CD86 (BD Pharmingen) -
CD206 IHC Anti-MRCI (Sigma) Target Retrieval Solution pH 9 (Dako), 20 min, 95uC
Static cytometry PE Mouse Anti-Human CD206 (BD Pharmingen) -
Gastrin IHC FLEX Polyclonal Rabbit Anti-Human Gastrin (Dako) Target Retrieval Solution pH 9 (Dako), 20 min, 95uC
Wnt1 IHC Polyclonal Rabbit Anti-Wnt1 (Sigma) Target Retrieval Solution pH 6 (Dako), 20 min, 95uC
*Procedure to unmask the antigen.
doi:10.1371/journal.pone.0098458.t002
Progastrin Modulates Macrophage Phenotype
PLOS ONE | www.plosone.org 2 June 2014 | Volume 9 | Issue 6 | e98458
Table 3. Primer sequences of specific PCR products for each gene analyzed.
Human Gene Sense Antisense Length (bp)
Wnt1 59-CGCCCACCCGAGTACCTCCA-39 59-TTCATGCCGCCCCAGGCAAG-39 110
Wnt3a 59-TACTCCTCTGCAGCCTGAAGCA-39 59-ATGGCGTGGACAAAGGCCGAC-39 322
Wnt5a 59-CTGCCCCAACTCGGGAGTCCAGG-39 59-AGGAATCCGAGCGGAGCGACC-39 147
Lgr5 59-GGCTCGGTGTGCTCCTGTCCT-39 59-TGCCTCAGGGAATGCAGGCC-39 484
b-actin 59-GGACTTCGAGCAAGAGATGG-39 59-AGCACTGTGTTGGCGTACAG-39 67
doi:10.1371/journal.pone.0098458.t003
Figure 1. Pattern of macrophage infiltration in colorectal cancer and healthy surrounding tissues. The immunoreactivity to CD68 (MF
marker, A–B), CD86 (M1-MF marker, C–D) and CD206 (M2-MF marker, E–F) was analyzed in colorectal cancer (B, D, F) and healthy surrounding mucosa
(A, C, E). (G) Quantitative analysis of positive cells for these molecules in a representative area of 0.22 mm2 (Scale bar = 0.2 mm). Bars represent mean
6SEM (n= 21). **P,0.01 and ***P,0.001 vs corresponding value in normal mucosa.
doi:10.1371/journal.pone.0098458.g001
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stage was defined according to the TNM staging system. The
study was approved by the Institutional Review Board of The
Hospital of Manises (Valencia). Written informed consent was
obtained from all patients.
Inmunohistochemistry
Serial sections (4 mm) of samples containing tumor and normal
mucosa from each patient were stained for gastrin, Wnt1, CD68 as
a macrophage marker, CD86 as a M1-macrophage marker or
CD206 as a M2-macrophage marker. Samples were subjected to
different methods of antigen retrieval depending on the epitope
(Table 2). Endogenous peroxidase activity was suppressed by
immersion in 0.3% hydrogen peroxide. Once blocked with 5%
horse serum, sections were incubated overnight (4uC) with the
corresponding primary antibody (Table 2). A horse anti-mouse/
rabbit biotinylated antibody (Vector Laboratories, CA, USA,
1:200) was used as a secondary antibody. The VECTASTAIN
elite ABC system Kit (Vector Laboratories, CA, USA), followed by
the DAB Enhanced Liquid substrate System for Immunohisto-
chemistry (Sigma-Aldrich, Missouri, USA) were used for develop-
ment. All tissues were counterstained with hematoxylin and the
specificity of the immunostaining was confirmed if analogous tissue
sections showed an absence of staining after using non-immune
immunoglobulin of the same isotype and at the same concentra-
tion as the primary antibody or after omitting the secondary
antibody.
A representative area (objective 40X, 6 fields, 0.22 mm2) from
tumoral tissue or adjacent normal glandular tissue was selected for
quantitative analysis of macrophage infiltration. Gastrin staining in
each sample was evaluated and a score for intensity from 1 to 4
was assigned. Only cancer epithelial cells reacted to gastrin
antibody and the intensity of the staining was very homogeneous
through the entire epithelial tumor compartment. All samples
were processed in parallel and an observer, unaware of the patient
number and different from the person who processed and
analyzed the macrophage immunostainings, assigned an score to
each patient based on the intensity of staining observed in three
pictures representative of different parts of the tumor.
Cell culture
Human peripheral blood mononuclear cells were isolated from
healthy donors by Ficoll density gradient centrifugation. Mono-
cytes were seeded in tissue culture plates and matured to
macrophages by culturing in X-Vivo 15 medium (BioWhittaker)
supplemented with 1% human serum and 20 ng/nl of recombi-
nant human M-CSF (Peprotech) at 37uC in 5% CO2 for up to 6
days. In order to obtain an M1 polarization, cells were incubated
with 1 mg/ml LPS (from Escherichia coli 0111:B4, Sigma-Aldrich)
plus 20 ng/ml human recombinant IFNc (Peprotech) for the last
24 hours. M2 polarization was obtained by treating cells with
20 ng/ml of human recombinant IL4 (Peprotech) for the last
48 hours of the culturing period. The maturation process as well
as the activation treatments were carried out in the presence or
Figure 2. Relationship between gastrin expression and the
pattern of macrophage infiltration in colorectal cancer sam-
ples. The number of total macrophages (CD68 + cells, B), M1-
macrophages (CD86+ cells, C), and M2-macrophages (CD206 cells, D),
in the tumor and normal surrounding tissue were analyzed in relation to
gastrin expression in tumoral tissue (A, score 1 to 4, scale bar
= 0.2 mm). A negative and significant correlation is observed between
the intensity of gastrin staining and the number of M2-macrophages in
normal mucosa and tumoral tissue (D).
doi:10.1371/journal.pone.0098458.g002
Progastrin Modulates Macrophage Phenotype
PLOS ONE | www.plosone.org 4 June 2014 | Volume 9 | Issue 6 | e98458
absence of different concentrations of progastrin (10211–1027M,
Abgent).
Caco-2 cells (American Type Culture Collection, VA, USA)
were cultured in MEM medium (Sigma-Aldrich) supplemented
with 20% inactivated bovine foetal serum, 100 U/ml penicillin,
100 mg/ml streptomycin, 2 mM L-glutamine, 100 mM sodium
pyruvate and 1% of non-essential amino acids.
Caco-2 cells were co-cultured with monocyte-derived macro-
phages using Transwell inserts (Corning Incorporated, MA, USA)
with a 0.4 mm porous membrane [12]. Monocytes were seeded on
these inserts and differentiated to macrophages in the presence or
absence of different concentrations of progastrin. On day 6 after
seeding, the inserts were placed on top of Caco-2 cells (t = 0) and
were maintained in co-culture for 24 hours.
The presence of the surface molecules CD86 (M1) and CD206
(M2) in cultured macrophages was analyzed by fluorescence
microscopy (microscope IX81, Olympus, Hamburg, Germany).
Macrophages were incubated with hoescht to identify the nuclei
and with fluorescent labeled antibodies against these targets
(Table 2). Fluorescence was analyzed with the static cytometry
software ScanR (.5000 cells/well).The concentration of the
cytokines IL12 (Th1) and IL10 (Th2, antiinflammatory) in cell
supernatants was determined by ELISA (Diaclone).
The number of Caco-2 cells after co-culture was counted in a
Newbauer chamber. Apoptosis in these cells was studied by flow
cytometry as bivariate Annexin V/PI analysis (Apoptosis Detec-
tion Kit, Abcam).
Total RNA from macrophages or Caco-2 cells was isolated by
using the extraction kit (Illustra RNAspin Mini, GE HealthCare
Life Science) and cDNA was obtained with the Prime Script RT
reagent Kit (Takara Biotechnology). Real-time PCR was per-
formed with the Prime Script Reagent Kit Perfect Real Time
Figure 3. Influence of progastrin on the phenotype of human monocyte-derived macrophages. Human peripheral monocytes were
derived to macrophages in the presence or absence of progastrin and the phenotype of the resultant macrophages evaluated by analyzing the
following parameters: expression of CD86 (A, C, n = 3); expression of CD206 (B, D, n = 3); secretion of IL12 (F, n = 4); and secretion of IL10 (G, n = 4). Bars
represent mean 6SEM. *P,0.05 and **P,0.01 vs corresponding value in vehicle-treated cells.
doi:10.1371/journal.pone.0098458.g003
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(Takara Biotechnology) in a thermo cycler LightCycler (Roche
Diagnostics, Mannheim, Germany). Specific oligonucleotides were
designed according to sequences shown in Table 3. Relative gene
expression was expressed as previously described [15].
Statistical analysis
Data are expressed as mean 6s.e.m. and were compared by
analysis of variance (one way-ANOVA) with a Newman-Keuls
post-hoc correction for multiple comparisons or a t-test when
appropriate. A P value ,0.05 was considered to be statistically
significant. The clinical correlations in human samples were
analyzed using the Pearson’s correlation coefficient.
Results
M2 macrophage number is increased in the tumoral area
We first analyzed the amount and phenotype of macrophages in
the non-tumor and tumor areas of colorectal cancer patients.
Immunohistochemistry for CD68 (macrophage marker), CD86
(M1 macrophage marker) and CD206 (M2 macrophage marker)
was performed in biopsy samples from colorectal carcinoma
resections. Of note, the number of macrophages was similar in
tumor and normal surrounding tissue, but the number of M1 and
M2 macrophages was significantly different between the two areas
(Figure 1). Tumor stroma contained a lower number of CD86(+)
cells than lamina propria of the normal tissue. In contrast, a higher
number of CD206(+) cells was encountered in tumoral tissue
Figure 4. Influence of progastrin on human M1 and M2 macrophages. Human monocyte-derived macrophages were stimulated with LPS
plus IFNc to obtain a M1-phenotype or with IL4 to obtain M2-macrophages in the presence or absence of progastrin, and the resultant phenotype
evaluated by analyzing the following parameters: expression of CD86 (A, n = 3); expression of CD206 (B, n = 5); secretion of IL10 (C, D, n = 5); and
secretion of IL12 (E, F, n = 5). Bars represent mean 6SEM. *P,0.05 vs corresponding value in vehicle-treated cells; + P,0.05 and ++P,0.01 vs
corresponding value in control cells.
doi:10.1371/journal.pone.0098458.g004
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compared with normal surrounding tissue, suggesting that tumor
development favors the differentiation of monocytes to M2
macrophages.
Gastrin expression is increased in the tumor but
negatively correlates with the number of M2
macrophages
Searching for mediators that could modulate the phenotype of
macrophages into the tumor we studied the role of gastrin peptides
on the expression of different macrophage markers in the biopsy
samples. Since the gastrin antibody used in this study recognizes
both gastrin and gastrin precursors, like progastrin, we cannot
discriminate between different gastrin peptides, but we observed
extensive immunoreactivity in tumor epithelial cells of biopsies
analyzed. Staining in each sample was evaluated and a score for
intensity from 1 to 4 was assigned (Figure 2A). No correlation was
observed between gastrin levels in tumors and the number of total
(CD68+ cells) or M1 (CD86+ cells) macrophages either in the
tumor or in normal tissue (Figures 2B and 2C). Surprisingly, the
number of M2 macrophages in tumoral and normal tissue
correlated negatively with gastrin expression. This correlation
was more significant in the tumor, where the peptide is
synthesized. Taken together these data suggest that gastrin
peptides synthesized by tumor cells reduces the number of M2
macrophages, without affecting the total macrophage number.
Progastrin decreases the differentiation of macrophages
towards a M2 phenotype
We hypothesized that progastrin could be responsible for the
effects observed on macrophage phenotype, because colon cancer
cells lack the enzymes necessary for complete gastrin maturation
[7]. To investigate whether progastrin can modulate the differen-
tiation of macrophages to a M1- or M2-phenotype we treated
human peripheral monocytes obtained from healthy volunteers
with several concentrations of progastrin and left them to
differentiate. Static cytometry experiments carried out with
specific fluorescent antibodies showed that progastrin reduced
the expression of the M2-marker CD206 in monocyte-derived
macrophages even at the lowest concentration analyzed. In
contrast, no changes in the expression of the M1-marker CD86
were detected. In addition, we measured the concentration of IL-
12 and IL-10 in the supernatant of monocyte-derived macro-
phages after 6 days of differentiation in the presence of increasing
doses of progastrin. The gastrin precursor elicited a significant
reduction of IL-10 secretion but did not alter the IL-12 levels
(Figure 3). Our data indicate that progastrin inhibits the expression
of M2-markers during macrophage differentiation without affect-
ing the expression of M1-markers.
In order to study the effect of progastrin on IL4-mediated
differentiation of macrophages towards a M2-phenotype we
incubated fully differentiated monocyte-derived macrophages with
IL-4 and different doses of progastrin for two days. Basal
macrophages treated with IL-4 showed a significant increase in
CD206 expression, a non-significant increase in IL-12 secretion
and similar IL-10 production than controls. Progastrin signifi-
cantly reduced the induction of CD206 by IL-4 and increased IL-
12 secretion to levels significantly higher than those observed in
control cells, while secretion of IL-10 remained unchanged.
However, differentiation of macrophages towards a M1-pheno-
type was not affected by progastrin. Treatment with LPS plus
Figure 5. Influence of progastrin on macrophage-derived Wnt ligands. Immunoreactivity to Wnt1 in the stroma of colorectal cancer in
relation to the expression of gastrin in the same tissue (scale bar = 0.2 mm) (A); and effects of the presence of progastrin during differentiation of
human peripheral monocytes to macrophages on mRNA expression of three different Wnt ligands in these macrophages (B–D, n = 5) and mRNA
expression of Lgr5 in co-cultured Caco-2 cells (E, n = 7). Bars represent mean 6SEM. *P,0.05 and **P,0.01 vs corresponding value in vehicle-treated
cells.
doi:10.1371/journal.pone.0098458.g005
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IFNc increased the expression of CD86, and the secretion of both
IL12 and IL10 in macrophages, but progastrin did not modify any
of these parameters (Figure 4).
Progastrin down-regulates Wnt ligands in macrophages
and increases cell death in co-cultured Caco2 cells
Next we analyzed whether the modulation of macrophage
phenotype by progastrin could affect the surrounding tumor cells.
We have recently reported that M2-macrophages synthesize and
secrete Wnt ligands which can modulate co-cultured epithelial cell
behavior [16] and in the present study we observed immunore-
activity for Wnt1 in cells of the tumor stroma. Qualitative
assessment of the expression of this Wnt ligand indicates that the
amount of positive cells decreases as gastrin production in cancer
cells increases (Figure 5A). A causal relationship between both
factors is pointed out by our in vitro studies showing that
macrophages maturated in the presence of progastrin present a
significantly reduced mRNA expression of three different Wnt
ligands (Wnt1, Wnt3a, and Wnt5, Figures 5B–5D). Functional
relevance of the down-regulation of the three Wnt ligands in
macrophages is demonstrated by the fact that Caco2 cells co-
cultured with progastrin-treated macrophages expressed less Lgr5
mRNA than Caco2 cells co-cultured with control macrophages
(Figure 5E). These data indicate that the effects of progastrin on
macrophage-derived Wnt ligands modulate the Wnt signaling
pathway in surrounding tumor cells.
Furthermore, co-culture of Caco-2 with progastrin-treated
macrophages resulted in a significant reduction in the total
number of epithelial cells together with an increased rate of
apoptosis (Figure 6).
Discussion
This study shows that macrophages infiltrating colorectal
tumors have a different phenotypic profile than those that are
present in the normal tissue surrounding the cancerous lesion, with
a higher proportion of the anti-inflammatory M2-macrophages
and significantly lower numbers of classically activated M1-
macrophages. Interestingly, our results indicate that gastrin
expression in tumoral tissue exerts a negative influence on the
number of tumoral M2-macrophages.
The expression of gastrin in tumoral epithelial cells correlates
negatively with the number of tumoral M2-macrophages and our
in vitro results suggest a causal relationship between both factors.
Human macrophages obtained by culturing peripheral monocytes
in the presence of progastrin showed a reduced expression of
CD206. Moreover, this peptide significantly prevented the
expression of CD206 when mature macrophages were stimulated
with the Th2 cytokine IL4 to induce an M2-phenotype. In
contrast, progastrin did not affect the expression of the co-
stimulatory molecule CD86 either in resting conditions or in
macrophages stimulated with LPS plus IFNc to develop an M1-
phenotype. Progastrin also affects the pattern of cytokine secretion.
Macrophages maturated in the presence of this peptide released
lower amounts of the anti-inflammatory cytokine IL10 while
maintaining normal release of the Th1 inducer IL12. In IL4-
stimulated macrophages, the effects on cytokine secretion were
different but in the same direction. In this case, IL10 release was
unaffected while the peptide facilitated IL12 secretion. Thus, it is
expectable that those macrophages that are under the influence of
progastrin in the cancerous tissue present a blunted anti-
inflammatory, immunosuppressive profile.
This effect is in line with the previously described proinflam-
matory action of gastrin [11–13]. We observed that gastrin
contributes to the inflammation induced by Helicobacter pylori in
rats probably through CCK-2 receptor activation in macrophages
while the stimulation of this receptor activates human endothelial
cells to promote monocyte adhesion. CCK-2 receptors can bind all
gastrin peptides, although their affinity for mature gastrin is
significantly higher than that demonstrated for progastrin. The
actions of the latter may be alternatively transmitted by the
recently characterized non-conventional receptor annexin-II [9].
Both kinds of receptors are present in macrophages and both
pathways promote macrophage activation [14]. Thus, the present
results reinforce the notion that gastrin peptides tend to contribute
to inflammation although different mechanism may be involved in
each case.
The influence of macrophages on cancer progression is due to
their effect on the immune response against the tumor but also to a
direct local effect on the surrounding epithelial cancer cells.
Macrophages can be a source of Wnt ligands [17], the oncogenic
pathway activated in the majority of colorectal cancers and a
significant contributor to cancer cell stemness [18,19]. Secretion of
these factors is especially relevant in a subpopulation of TAMs that
seem to play a particular role in tumor invasiveness by promoting
angiogenesis and tumoral cell migration through Wnt-signaling
[20,21]. Wnt1 was detected in cells of the tumor stroma and its
Figure 6. Influence of progastrin-treated macrophages on
colorectal cancer cells. The effects of human monocyte-derived
macrophages obtained in the presence or absence of progastrin on the
number (A) and the rate of apoptosis (B) of Caco-2 cells were analyzed
in a co-culture system (24 h, n = 4). Bars represent mean 6SEM. *P,
0.05 vs corresponding value in vehicle-treated macrophages, +P,0.05
and ++P,0.01 vs cells incubated with an empty insert (w/o MF).
doi:10.1371/journal.pone.0098458.g006
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presence tended to decrease, as the level of gastrin in the tumor
increased. We have recently observed that secretion of Wnt
ligands is specifically increased in M2 macrophages, which
promote Wnt/b-catenin signaling pathway and the consequent
proliferative activity in co-cultured colon cancer cells [16]. Our
present results show that macrophages maturated in the presence
of progastrin express lower amounts of three different Wnt ligands
and provoke a significant reduction in the number of co-cultured
Caco-2 cells. This effect occurs with a concomitant decrease in the
expression in these colonic cells of Lgr5, a Wnt target gene [22]
that potentiates Wnt/b-catenin signaling [18]. Moreover, macro-
phages maturated in the presence of progastrin tend to increase
the apoptosis rate in Caco-2 cells, an effect that may also be
related with reduced Wnt signaling [23]. Thus, the phenotypical
changes induced by progastrin in macrophages modify their
influence on colon cancer epithelial cells resulting in a diminished
number of these cells probably by a combination of reduced
proliferation and increased apoptotic cell death. Additionally, the
reduced production of Wnt ligands induced by progastrin may also
contribute to the described phenotypical changes induced by this
peptide since an autocrine effect of Wnt5a in macrophages to
reduce the expression of IL12 in response to bacterial products has
been described [24].
From our results we can infer that gastrins, by inhibiting the
acquisition of an M2-phenotype in local macrophages, may
regulate cancer progression. It is clear that M2 macrophages
stimulate the growth of colon-cancer epithelial cells in vitro and
experimental studies demonstrate that M2-macrophages in the
tumor promote colon cancer in mice [25–27]. In human colorectal
cancers, the effect of M2-macrophages seems more complicated
and affected by several factors like their spatial distribution [4], the
relative amount of M1 macrophages [5] or the stage of the disease
[4]. Although their presence have been seen as a negative
prognostic factor by some authors [28], others suggest that M2
macrophages have a less hazardous effect in human colorectal
cancer than in other settings and point to the idea that some local
factor specifically present in this kind of tumors may be down-
regulating their tumor promoting action [4,5,29]. Keeping in
mind that M1 and M2 macrophages are not clonally different sets
of cells but the extremes of a wide spectrum of intermediate
phenotypes and that classification of a cell as an M2 macrophage
may be biased by the molecular marker selected in each case, we
launch the idea that those macrophages identified as M2 in these
studies may be less deleterious because of progastrin.
A direct proliferative function of progastrin on epithelial cells
has been clearly demonstrated in isolated cells and mice, and
experimental studies with transgenic animals suggest that overex-
pression of gastrins in the presence of DNA-damaging agents
enhances carcinogenesis. This evidence has prompted several
pharmacological strategies to neutralize the activity of gastrin
peptides, with successful results in murine models but, unfortu-
nately, few and indefinite results in patients [30]. Our findings
suggest that, at least in humans, progastrin can play a multifaceted
role in the progression of colorectal tumors, as its proliferative
activity on epithelial cells would be opposed by a potentially anti-
tumoral action exerted on macrophages. The relevance of this
effect on immune cells for the global activity of progastrin awaits
evaluation by future research.
Conclusions
Our study indicates that gastrin peptides synthesized by colon
cancer cells have macrophages as their targets and probably affect
the inflammatory infiltrate of the tumor, which in turn affects
cancer progression. The inhibition of M2-polarization induced by
progastrin would counteract their proliferative activity and,
although it is difficult to estimate the magnitude of this effect,
this observation should be taken into account when analyzing the
therapeutic value of gastrin immunoneutralization [31].
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